iconstar paper   Hepatitis C Articles (HCV)  
Back grey arrow rt.gif
 
 
Mavyret + Sofosbuvir (RBV) for Sof/Vel/Vox Failures
 
 
  Glecaprevir/pibrentasvir & sofosbuvir for 16 weeks without ribavirin is safe and highly effective retreatment for patients who have failed an NS5A inhibitor containing antiviral regimen

0827231

Excellent Efficacy and Safety of Sofosbuvir, Glecaprevir, Pibrentasvir and Ribavirin for Retreatment of Chronic Hepatitis C after Sofosbuvir, Velpatasvir and Voxilaprevir Failure SF

0827232

Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings
 
Sofosbuvir, Glecaprevir, Pibrentasvir, and Ribavirin as a Rescue Therapy in Difficult-to-Treat HCV Patients
 
Sofosbuvir + Glecaprevir/Pibrentasvir (G/P) in patients with difficult to treat HCV infection. Final results of the French compassionate use

0827233

0827234

  
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org